{"filing":{"accession_number":"0001104659-26-087110","cik":"0001390478","ticker":"SLS","company_name":"SELLAS Life Sciences Group, Inc.","form":"8-K","filing_date":"2026-07-27","report_date":"2026-07-24","primary_document":"tm2621415d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465926087110/tm2621415d1_8k.htm"},"events":[{"id":20743,"run_id":18668,"accession_number":"0001104659-26-087110","anchor_item_number":"2.02","event_type":"financial_other","event_domain":"financial","is_material":false,"confidence":0.75,"summary":"The Company disclosed an unaudited, preliminary cash position estimate of $138.3 million as of June 30, 2026, subject to completion of financial closing procedures. This is a routine interim financial update rather than a formal earnings release or material financial event.","company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","filing_date":"2026-07-27","form":"8-K","submitted_at":null,"items":[{"id":20200,"accession_number":"0001104659-26-087110","item_number":"2.02","item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":false,"confidence":0.75,"reasoning":"The disclosure reports an unaudited, preliminary cash position estimate ($138.3 million as of June 30, 2026) subject to completion of financial closing procedures. This is a routine interim financial update that does not constitute a formal earnings release (which would typically include comprehensive results and be attached as an exhibit), nor does it disclose results of operations or material financial events. The company explicitly notes the estimate may differ materially from final statements, indicating this is a preliminary cash position notice rather than a material financial event affecting investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T20:35:51.648844+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":20744,"run_id":18668,"accession_number":"0001104659-26-087110","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"summary":"The Company disclosed an adverse arbitration decision rendered on July 24, 2026, dismissing its claims against 3D Medicines and imposing approximately $1.0 million in legal fees and costs on the Company. This outcome materially affects the Company's financial position and its rights under the exclusive license agreement for galinpepimut-S, with $191.5 million in potential future milestone payments at stake.","company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","filing_date":"2026-07-27","form":"8-K","submitted_at":null,"items":[{"id":20201,"accession_number":"0001104659-26-087110","item_number":"8.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"The Company discloses an adverse arbitration decision rendered on July 24, 2026, dismissing its claims against 3D Medicines and imposing approximately $1.0 million in legal fees and costs on the Company. This represents a material litigation outcome affecting the Company's financial position and its rights under the exclusive license agreement for galinpepimut-S, with $191.5 million in potential future milestone payments at stake.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T20:35:51.648844+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20200,"accession_number":"0001104659-26-087110","item_number":"2.02","item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":false,"confidence":0.75,"reasoning":"The disclosure reports an unaudited, preliminary cash position estimate ($138.3 million as of June 30, 2026) subject to completion of financial closing procedures. This is a routine interim financial update that does not constitute a formal earnings release (which would typically include comprehensive results and be attached as an exhibit), nor does it disclose results of operations or material financial events. The company explicitly notes the estimate may differ materially from final statements, indicating this is a preliminary cash position notice rather than a material financial event affecting investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T20:35:51.648844+00:00","company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","filing_date":"2026-07-27"},{"id":20201,"accession_number":"0001104659-26-087110","item_number":"8.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"The Company discloses an adverse arbitration decision rendered on July 24, 2026, dismissing its claims against 3D Medicines and imposing approximately $1.0 million in legal fees and costs on the Company. This represents a material litigation outcome affecting the Company's financial position and its rights under the exclusive license agreement for galinpepimut-S, with $191.5 million in potential future milestone payments at stake.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T20:35:51.648844+00:00","company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","filing_date":"2026-07-27"}]}